Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin
Manga Motrapu(LMU Klinikum), Lidia Anguiano(LMU Klinikum), Irene Mesas(LMU Klinikum), Monika Świderska(LMU Klinikum), Giulia Antonelli(University of Florence), Yutian Lei(Quanzhou Normal University), Paola Romagnani(Meyer Children's Hospital), Jia Fu(Harbin Medical University), Julian A. Marschner(Ludwig-Maximilians-Universität München), Maria Lucia Angelotti(University of Florence), Hans‐Joachim Anders(LMU Klinikum), Kyung Lee(Icahn School of Medicine at Mount Sinai), Laura Martínez Valenzuela(Bellvitge University Hospital)
Cited by 29
Related Papers
Acute kidney injury
|Nature Reviews Disease Primers|2021|1.6k
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
|Kidney International|2011|361
Glomerular endothelial cell injury and cross talk in diabetic kidney disease
|American Journal of Physiology-Renal Physiology|2014|274
Single-Cell RNA Profiling of Glomerular Cells Shows Dynamic Changes in Experimental Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2019|215